Nanopath closed a $25M Series B on November 10 to take its point-of-care vaginitis test into an FDA 510(k) clinical study. Norwest and the MedTech Convergence Fund at SV Health Investors co-led. The Labcorp Venture Fund joined as a strategic investor, alongside Elderberry Ventures, GingerBread Capital and Alumni Ventures. About $2M of the total is non-dilutive grant money.
The Cambridge, Massachusetts company reads molecular targets with plasmonic biosensing, an optical method that detects nucleic acid without amplifying it. Dropping the amplification step is what gets a result to 15 minutes in a clinic instead of hours in a lab. The test is not cleared or approved.
Co-CEOs Alison Burklund and Amogha Tadimety founded Nanopath in 2020, and it has now raised more than $46M. Proceeds go to manufacturing scale-up, the 510(k) study, and clinical and commercial hiring, with UTI and STI panels named as later targets. The strategic check from Labcorp is the detail worth watching. Reference labs do not often fund point-of-care tests that cut into their own send-out volume.